SEC Tracker
Get the app
NGNE · XBRL financial data

Neurogene financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NGNE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*—92500*—000*——
Research and development61736,514*13,54115,74416,28515,347*17,76019,36617,24120,639*25,15025,468
General and administrative4,952(1,281)*5,2385,3155,8956,165*8,1596,7156,5576,890*8,19911,202
Total operating expenses5,56931,815*18,77921,05922,18021,512*25,91926,08123,79827,529*33,34936,670
Operating income (loss)(5,569)(31,815)*(18,779)(20,134)(22,180)(21,512)*(25,919)(26,081)(23,798)(27,529)*(33,349)(36,670)
Interest income650781*2,3202,0351,8422,270*3,2062,9282,7392,673*2,2612,046
Interest expense43*3432*2111*00
Income tax expense (benefit)—————year only———year only——
Net income (loss)(4,526)(15,502)*(16,921)(18,492)(20,217)(19,514)*(22,647)(22,016)(20,953)(24,735)*(30,934)(34,488)
Earnings per share, basic‡ USD per share(1.64)—(1.00)(1.09)(1.19)(1.00)*(1.08)(1.05)(0.99)(1.12)*(1.39)(1.53)
Earnings per share, diluted‡ USD per share(1.64)—(1.00)(1.09)(1.19)(1.00)*(1.08)(1.05)(0.99)(1.12)*(1.39)(1.53)
Weighted average shares, basic‡ thousands of shares2,775—16,90416,94216,95319,456*20,99621,05521,16822,075*22,30622,552
Weighted average shares, diluted‡ thousands of shares2,775—16,90416,94216,95319,456*20,99621,05521,16822,075*22,30622,552
  • ‡ Per-share figures and share counts are adjusted for the 1-for-4 stock split (December 2023); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (NGNE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents25,226148,210150,140111,03266,633136,58670,77158,81371,005103,845124,161112,485
Short-term investments—48,94719,39342,87372,360175,819221,831215,706194,405165,168119,021112,907
Marketable securities53,281———————————
Prepaid and other current assets—3,1914,6085,2444,6543,5183,7964,4675,1092,7573,5653,521
Total current assets79,893200,348174,141159,149143,647315,923296,398278,986270,519271,770246,747228,913
Property and equipment, net48417,17416,47516,06416,06815,42214,80714,24913,48412,79212,50411,734
Right-of-use asset8,6853,6813,5653,3813,1933,0002,8032,6012,3942,6482,4582,263
Total assets89,586222,573195,350179,823164,120335,730315,301297,316287,832288,604263,141244,364
Accounts payable—2,5961,5221,7241,6841,3363,0632,0601,5441,9534,6853,294
Accrued liabilities—17,4956,8247,14410,4389,7316,8499,0979,42410,75611,13415,185
Total current liabilities5,21222,97311,81813,07315,80015,15714,09415,44014,71016,41118,86621,505
Lease liability, non-current9,13412,30211,64210,91510,1709,4038,6067,8237,0976,8226,0795,316
Total liabilities14,35136,54924,57324,80926,70625,35523,50624,06122,29223,71725,35827,231
Accumulated deficit(471,870)(187,154)(204,075)(222,567)(242,784)(262,298)(284,945)(306,961)(327,914)(352,649)(383,583)(418,071)
Total stockholders' equity75,235186,024170,777155,014137,414310,375291,795273,255265,540264,887237,783217,133
Total liabilities and equity89,586222,573195,350179,823164,120335,730315,301297,316287,832288,604263,141244,364
Common shares outstanding (cover page)‡ thousands of shares2,34912,85312,98012,99414,85514,93014,26214,27215,49015,57415,80220,011
  • ‡ Per-share figures and share counts are adjusted for the 1-for-4 stock split (December 2023); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (NGNE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(4,526)(15,502)*(16,921)(18,492)(20,217)(19,514)*(22,647)(22,016)(20,953)(24,735)*(30,934)(34,488)
Stock-based compensation172*(276)*1,0452,314*2,474*2,487*4,0483,408*3,365*3,362*3,6297,862*
Depreciation and amortization8002,779*814800800785*749800800776*847813*
Net cash from operating activities(4,269)*year only(21,650)(15,893)*(15,564)*(17,496)*(20,774)(19,462)*(19,508)*(17,429)*(26,119)(23,761)*
Purchases of property and equipment0*(230)*65460*167*116*780148*127*128*281354*
Net cash from investing activities(1,614)*16,956*29,935(23,614)*(28,966)*(102,616)*(45,045)7,450*21,990*29,609*46,2406,104*
Proceeds from issuing common stock—year only———0*——9,800*20,580*——
Net cash from financing activities(1)*92,843*(6,524)399*131*190,065*454*9,710*20,660*1955,981*
Net change in cash(5,884)*79,728*1,761(39,108)*(44,399)*69,953*(65,815)(11,958)*12,192*32,840*20,316(11,676)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Neurogene112,485not reported(23,761)*20.0M9.5 quarters 10-QJun 30, 2026
Puma Biotechnology36,53756,5021,624*51.6M— 10-QJun 30, 2026
Eledon Pharmaceuticals6,803not reported(22,677)*81.3M3.9 quarters 10-QJun 30, 2026
Voyager Therapeutics35,7693,165(25,842)*61.6M4.5 quarters 10-QJun 30, 2026
Aclaris Therapeutics19,1671,629(19,847)*147.2M4.6 quarters 10-QJun 30, 2026
Alpha Cognition41,3846,093(6,859)*21.8M6.0 quarters 10-QJun 30, 2026
Sangamo Therapeutics27,5861,442(19,282)414.3M1.4 quarters 10-QMar 31, 2026
Vistagen Therapeutics16,991not reported(14,707)44.4M2.2 quarters 10-QJun 30, 2026
Monopar Therapeutics52,7580*(3,247)*6.7M32.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.